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ABSTRACT
Guidelines to control and prevent methicillin-resistant Staphylococcus aureus (MRSA) infection are
available in many countries. Infection control and prevention teams determine local strategies using
such national guidelines, but not all guidelines involve a rigorous assessment of the literature to
determine the strength of the recommendations. Available guidelines drafted by national agencies or
prominent professional organisations in Germany, New Zealand, North America, The Netherlands,
Ireland and the UK were reviewed. Significant literature reviews were a component of guidelines from
the UK and North America. Recommendations were not graded on the strength of the evidence in
guidelines from New Zealand and The Netherlands. The Netherlands, a country with a very low
prevalence of MRSA, had the simplest set of guidelines. Few of the recommendations in any of the
guidelines achieved the highest grading, i.e., based on well-designed, experimental, clinical or
epidemiological studies, even though the logic of the proposed measures is clear. The onset of
community-acquired MRSA is reflected in the recent publication of guidelines from North America.
New developments, such as rapid testing and mathematical modelling, are of importance in helping to
control MRSA in settings of both low and high endemicity. National guidelines are increasingly
evidence-based, although good scientific studies concerning some aspects of MRSA control are lacking.
However, general principles, e.g., early detection and isolation, are recommended by all guidelines.
There is still a role for consensus and the opinion of experts in devising national guidelines.
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INTRODUCTION
International variation is important when review-
ing the prevalence of methicillin-resistant Staphy-
lococcus aureus (MRSA), as it may indicate how to
successfully control spread. While MRSA has
been encountered in most, if not all, national
healthcare services, there are countries in which
the prevalence of MRSA is relatively low. Thus, in
The Netherlands, a country that adopts a ‘search-
and-destroy policy’, a recent study found that
only 0.03% of patients were carriers of MRSA.
Furthermore, genotyping revealed that most
MRSA isolates in The Netherlands were unre-
lated, and therefore that acquisition was probably
not a result of cross-infection [1].
Although epidemic MRSA first appeared on the
east coast of Australia in the early 1980s, it was
only in the late 1980s that multiresistant MRSA
emerged in Western Australia. The highest noti-
fication rates were recorded in the Kimberley
region, a largely rural area, with a marked
increase being recorded between 1991 and 2002
[2]. However, the majority of isolates in this area
were community-acquired, which was in contrast
to the situation in other parts of Australia and
most other countries during the same period.
Furthermore, few of the isolates in Western
Australia were multidrug-resistant [2].
During the early 1990s, two outbreaks of MRSA
occurred in a hospital in Finland, but were
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brought under control through rigorous system-
atic screening of all patients and improved infec-
tion control practices. It was concluded that
controlling, or even eliminating, MRSA is possible
if aggressive countermeasures are taken before
the organism becomes endemic [3]. Since 1997,
the number of cases of MRSA notified in Finland
has increased from 2.3 to 11.5 cases ⁄ 100 000 pop-
ulation, but these cases are seen largely in the
elderly and in long-term care facilities, rather than
in acute hospitals [4].
In Europe, the European Antimicrobial Resist-
ance Surveillance System routinely collects anti-
microbial susceptibility data for S. aureus and
other important bacterial pathogens causing
bloodstream infection (BSI). As a proportion of
all S. aureus isolates causing BSI, MRSA accoun-
ted for >30% of cases in Bulgaria, Greece, Ireland,
Italy, Malta and the UK during 1999–2002 [5].
Only in Slovenia has there been a significant
recent decrease in the prevalence of MRSA caus-
ing BSI, as recorded by the European Antimicro-
bial Resistance Surveillance System.
In the USA, changes in the epidemiology
of MRSA have been recorded in the National
Nosocomial Infections Surveillance System. A
review of infections in intensive care units (ICUs)
in US hospitals between 1992 and 2003 revealed
that 64% of all S. aureus isolates were MRSA by
2003, with an overall increase of 3.1% annually
[6]. Interestingly, the overall increase in MRSA
was accompanied by a decrease in multidrug
resistance, suggesting that community-acquired
MRSA strains are entering US hospitals.
Harbarth et al. [7] investigated the differences
in the epidemiology of multiresistant bacteria in
the USA and Germany. Antibiotic resistance rates
were generally lower in Germany than in the
USA, but are not below those of some other
European countries such as The Netherlands. The
reasons for the dissimilarities between the USA
and Germany are not clear, but may be associated
with differences in the utilisation of a laboratory
to diagnose infection and the precise laboratory
procedures used, as well as clonal differences
among circulating bacteria, antibiotic prescribing
practices, differences in the patient population
and cultural factors [7]. For these and other
reasons, reports from different countries are
difficult to compare, especially when reviewing
the control of outbreaks or when comparing
prevalence rates. The relative success of infection
control and prevention measures is determined
by many factors, such as the facilities avail-
able (e.g., the number of isolation beds and
staffing levels), the executive authority afforded
to the infection control and prevention team by
the hospital administration, bed occupancy rates,
and compliance with best practice (e.g., hand
hygiene) [8]. Furthermore, the interaction be-
tween these interventions and other aspects of
healthcare is probably quite complex. For exam-
ple, the impact of reduced nursing staff levels
may be counterbalanced by a change in case-mix
towards increased numbers of lower-risk patients.
In addition, the priority given to the prevention of
healthcare-associated infection in some countries,
such as The Netherlands, has been greater than
elsewhere for many years. Many guidelines con-
cerning the prevention and control of MRSA are
increasingly evidence-based. This review com-
pares national guidelines from different countries.
COMPARISON OF NATIONAL
GUIDELINES
Nine sets of guidelines that were accessible were
compared, two of which focus on community
MRSA.
The guidelines for Germany were published in
1999 and were produced by the Robert Koch
Institute, Berlin, Germany [9]. This is a succinct
document with a general introduction, followed
by a series of recommendations that are graded
according to the strength of the evidence. How-
ever, only two grades are used. Advice on
controlling MRSA includes screening, isolation,
decolonisation, etc. An information sheet for
patients is included and the document cites 20
references. An addendum to these guidelines was
issued by the Robert Koch Institute by means of a
bulletin in 2004, in which the indications for
MRSA screening were extended to include, e.g.,
patients with skin ulcers.
The guidelines for New Zealand were pub-
lished by the New Zealand Ministry of Health in
2002, and were developed by a group of eight
individuals [10]. These guidelines include a brief
introduction with reference to recent data
concerning MRSA in New Zealand. This is
followed by a series of sections in which control
measures are briefly reviewed and recommenda-
tions are outlined. Sections include modes of
transmission, screening, hand hygiene, isolation,
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etc. The document contains six appendices,
including a standardised letter for general
(family) practitioners, and a list of 76 references.
Guidelines produced by the Society for Hospi-
tal Epidemiology in America, with the assistance
of individuals from Europe and Canada, were
published in 2003. These guidelines also include
recommendations for the control of multidrug-
resistant strains of enterococci and are prefaced
by an extensive literature review [11]. Recom-
mendations are outlined under six headings, and
are graded according to the evidence available
from the literature; e.g., Ia indicates that the
recommendation is based upon well-designed
experimental, clinical or epidemiological studies.
However, although the evidence reviewed was
based on studies published between 1966 and
2002, many of the recommendations are not
supported by strong scientific data, despite the
fact that they have met with widespread appro-
val. In total, 353 references are cited, but these
also include references specific for multidrug-
resistant enterococci.
A Dutch working party on infection prevention
produced guidelines for The Netherlands in
2005 (http://www.wip.nl/UK/free_content/
Richtlijnen/MRSA(1).pdf). This is a brief docu-
ment with no authors listed and only 12 references
citied. The document contains eight sections,
which include risk categories, treatment of carriers,
etc. The recommended approach reflects the low
prevalence of MRSA and the ‘search-and-destroy’
policy that exists in The Netherlands. For example,
an epidemic ofMRSA is defined as occurringwhen
two or more patients in a hospital are colonised or
infected with the same strain.
In Ireland, a specialist sub-committee of eight
individuals drafted guidelines that were pub-
lished in 2005 [12], following a review of the
literature and guidelines from some other coun-
tries. The recommendations were graded accord-
ing to the strength of the evidence, with four
grades in all. The recommendations are divided
into general measures for infection control, and
specific measures to control and prevent MRSA
infection. Finally, the document contains five
appendices that include guidance on laboratory
methods for detection and recommendations
concerning hand hygiene.
In the UK, there have been national guidelines
for the control and prevention of MRSA infection
since 1986 [13]. The most recent guidelines were
published in 2006 and were the result of cooper-
ation between three professional societies, i.e., the
British Society of Antimicrobial Chemotherapy,
the Hospital Infection Society and the Infection
Control Nurses Association, with the involvement
and support of the UK Department of Health. The
eight-member group commissioned a systematic
review of evidence that searched six major
databases for relevant literature between 1996
and 2004 (the previous guidelines incorporated a
review of the literature up until 1998), with a
quality assessment of the data being extracted.
Because of limitations in time and resources, only
five areas were reviewed, i.e., screening, surveil-
lance, isolation and cohorting, decolonisation, and
environmental cleaning, with 6983 citations being
assessed [14]. The UK guidelines were very much
based on this systematic literature review of
the evidence, which was used to underpin the
recommendations. The grades of evidence range
from Ia to no recommendation, and recommen-
dations are provided under seven headings.
In Scotland, a group of professionals convened
by the Royal College of Physicians of Edinburgh
and the Royal College of Physicians and Surgeons
of Glasgow has provided guidance on the hospi-
tal management of MRSA [15]. This document is
similar in many respects to the UK guidelines in
terms of the specific advice, but no weighting is
given to the recommendations. However, the
authors emphasise the importance of clinical risk
assessment and targeted surveillance. The docu-
ment also includes a section on glycopeptide-
resistant ⁄ glycopeptide-intermediate S. aureus.
During 2006, two further sets of guidelines on
the control and management of community
MRSA were published in North America. Guide-
lines published by the CDC in the USA (http://
www.cdc. gov/incidod/dhqp/ar_mrsa_c.html) do
not include a formal literature review, but offer
helpful, sensible and practical advice in a number
of areas. The importance of early clinical suspi-
cion of infection and appropriate use of the
laboratory for diagnostic purposes is emphasised,
and the critical role of the use of appropriate
antibiotics for treatment is highlighted. General-
ised screening for community-acquired MRSA is
not recommended. A further set of guidelines
from Canada includes a literature review, with
grading of the recommendations according to the
strength of the evidence [16]. Sections concerning
when to suspect community-acquired MRSA,
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treatment of infections, screening, and the role of
decolonisation regimens in certain circumstances
are included, as well as advice concerning general
prevention measures, such as encouraging indi-
viduals to maintain good personal standards of
hygiene.
A summary of the main features of these
guidelines is provided in Table 1. Most of these
guidelines have attempted to grade the recom-
mendations on the basis of the available evi-
dence. However, there are few recommendations
that are graded Ia or equivalent, i.e., indicating
that the evidence is based on sound experimental,
clinical or epidemiological studies. Nonetheless,
there are no major differences among the various
guidelines in terms of their approach to control
and prevention, i.e., early detection through
surveillance, isolation or cohorting, decolonisa-
tion, etc. The importance of antibiotic steward-
ship is a specific heading in all but the German
guidelines [9]; however, these guidelines are the
oldest and focus largely on hygiene and infection
control. There are specific sections covering the
control and prevention of MRSA in the commu-
nity in the guidelines from New Zealand [10] and
Ireland [12], while the guidelines from the UK
[13] and Germany [9] indicate that they were
drafted and developed for hospitals and other
healthcare facilities. Specific guidelines for com-
munity-acquired MRSA have been published in
the USA (http://www.cdc.gov/incidod/dhqp/
ar_mrsa_c.html) and Canada [16].
Guidelines from Ireland [12] and the UK
[13–15] have specific sections covering the control
and prevention of MRSA strains that are inter-
mediately or fully resistant to glycopeptide anti-
biotics. However, in the North American
guidelines, advice concerning the control of these
bacteria is provided in some of the specific
recommendations for MRSA and vancomycin-
resistant enterococci [11].
THE QUALITY OF EVIDENCE TO
SUPPORT MRSA GUIDELINES
There is increasing evidence of the need to control
MRSA in hospitals, from both a clinical and a
financial perspective. BSI is potentially fatal in
many patients, and there has been much discus-
sion over many years as to whether the prognosis
for patients withMRSA is better or worse than that
for patients with methicillin-susceptible isolates,
after allowing for other factors such as underlying
disease. However, a meta-analysis of studies of
BSI caused by MRSA has confirmed that there is a
significant increase in mortality associated with
MRSA BSI, independently of other factors [17].
Although the expense incurred in controlling
MRSA may be considerable, several economic
evaluations have indicated that this is cost-effect-
ive in terms of reducing the costs of infections
caused by MRSA. In a comparison of two neona-
tal ICUs, one of which instituted control measures
in a stepwise fashion rather than simultaneously,
the cost arising from the delayed approach was
US $49–69 million (Euro 38–52 million), as com-
pared with US $1.3 million (Euro 1 million) when
the measures were introduced effectively and
quickly [18]. In a retrospective cohort study of
patients with MRSA BSI that allowed for con-
founding variables, there was a two-fold increase
in hospital costs and a 1.5-fold longer length of
hospital stay as compared with patients with BSI
caused by methicillin-susceptible S. aureus [19].
Wernitz et al. [20] assessed the costs of screening
for MRSA in Germany, and the cost-savings from
preventing hospital-acquired MRSA, over a
19-month period during which 539 patients were
screened. After allowing for the actual costs of
screening, the screening programme prevented
48% of predicted hospital-acquired MRSA infec-
tions, and allowed a net annual cost-saving of
Euro 110 237. A case-control study conducted in a
medical ICU in France demonstrated that select-
ive screening and isolation of carriers upon ICU
admission was cost-effective when there was a
14% reduction in MRSA infection rates [21].
When data from local hospitals are extrapolated
to the national level, the considerable financial
burden that MRSA represents becomes clear. Kim
et al. [22] estimated that the cost of MRSA to the
Canadian Health Service in 1998 was in the range
of Can $42–59 million (Euro 27–38 million).
Much of the evidence on which national guide-
lines are based includes non-controlled trials or
outbreaks, for which the natural history is vari-
able, unpredictable and may be governed by local
factors. In the literature review that accompanies
the current UK guidelines [14], many of the
conclusions are not based on controlled trials
or their equivalent, but on non-experimental,
descriptive studies.
Some of the difficulties and shortcomings of
studies performed in areas of high endemicity are
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Table 1. National guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus (MRSA) infection
Country, year of
publication
No. of
authors
Professional group
or society Methodology
Major
recommendation ⁄
headingsa
Strength of
recommendationsb
(% in each category)
No. of
references
cited
Germany,
1999
(addendum
in 2004)
7 Robert-Koch Institute,
Berlin
Descriptive
recommendations
graded
General
Isolation
Hand hygiene
Disinfection ⁄ cleaning
Surgery
Screening
Decolonisation
Patient transfers ⁄discharges
Ib-II (92)
II-1 (8)c
20
New Zealand,
2002
8 Ministry of Health Descriptive;
recommendations
not graded
Antibiotic use
Screening (patient and staff)
Hand hygiene
Isolation
Decolonisation
Environmental cleaning
Patient transfers
Outbreak control
Community MRSA
National surveillance
Microbiology procedures
N ⁄A 75
USA ⁄Canada,
2003
7 SHEA Literature review,
1996–2002
Evidence categorised
and recommendations
graded
Surveillance
Hand hygiene
Barrier precautions
Antibiotic stewardship
Decolonisation
Other
Ia-6 (15)
Ib-25 (64)
Ic-0
II-8 (21)c
353
The Netherlands,
2005
None
cited
Dutch Working
Party on Infection
Control
Descriptive;
recommendations
not graded
Risk categories
Measures for patients
Treatment (decolonisation)
Isolation
Measures for staff
Proclaiming an epidemic
N ⁄A 12
Ireland,
2005
8 National Expert
Committee
Review of literature and
other national
guidelines;
recommendations
graded
General measures
Antibiotic stewardship
Surveillance ⁄ screening of
patients and staff
Isolation ⁄ cohorting
Eradication (decolonisation)
Glycopeptide-intermediate and
-resistant Staphylococcus aureus
Control of MRSA in the
community
Overview and future
research ⁄developments
A-2 (3)
B-18 (24)
C-28 (37)
D-27 (36)d
95
UK,
2006
8 British Society for
Antimicrobial
Chemotherapy,
Hospital Infection
Society,
Infection Control
Nurses
Association
Systematic
acompanying literature
review;
recommendations
graded
Surveillance
Antibiotic stewardship
Screening (patients and staff)
Decolonisation
Patient management (including
isolation, patient transfers,
discharge, cleaning)
Nursing staff workload
Vancomycin-intermediate and
-resistant S. aureus
Ia-6 (9)
Ib-34 (50)
Ic-2 (3)
II-25 (37)c
No
recommendation-1
(1)
195
Scotland,
2006
11 Scottish Infection
Standards and
Strategy Group
(RCPE, RCP&SG)e
Descriptive;
recommendations
not graded
Risk assessment
Targeted surveillance
Management (nursing)
Isolation
Screening of patients and staff
Clearance
NA 104
USA,
2006
34 CDC-convened
meeting of experts
Descriptive;
recommendations
not graded
Diagnosis
Management, including
appropriate antibiotics
Standard infection control
precautions
NA 103
Canada,
2006
20 Canadian Expert
Panel
Literature review;
recommendations
graded
Management (diagnosis and
treatment)
Screening and decolonisation
Population surveillance
Prevention
Directions for future research
AI-I
AII-I
AIII-37
BII-2
BIII-38
CIII-10f
161
aThe major areas in which specific recommendations are provided.
bSource not always provided.
cCDC-type gradings.
dEvidence-based categorisation derived by Thames Valley University, London, UK.
eRoyal College of Physicians of Edinburgh, Royal College of Physicians and Surgeons of Glasgow.
fInfectious Disease Society of America Guidelines.
NA, not applicable; SHEA, Society for Healthcare Epidemiology of America.
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illustrated by a prospective 1-year study per-
formed in three ICUs in London, UK, which failed
to show the benefit of isolation in single rooms or
of cohorting of patients with MRSA colonisation
who were identified upon admission or upon
weekly screening [23]. However, in an accom-
panying editorial [24], the limitations of the study
are highlighted. These include a failure to screen
all patients on admission, a failure to ensure that
physicians and other healthcare providers, and
not just nurses, were specifically designated to
look after MRSA-positive patients, and poor com-
pliance (only 21%) with hand hygiene recommen-
dations. In addition, the delay in obtaining the
results of MRSA screening, up to 72 h with
culture-based methods, meant that isolation or
patient cohorting was delayed. This delay, com-
bined with a failure to use dedicated equipment
when a patient was in isolation, may have com-
promised the effectiveness of isolation as a control
measure. Overall, this study highlighted some of
the difficulties in conducting controlled trials of
interventions in settings where MRSA is endemic,
because of delays in identification of MRSA-
positive patients and problems in ensuring >90%
compliance with best professional practice. These
difficulties are especially important in healthcare
systems in which bed-occupancy rates are high
and isolation rooms are often unavailable.
Two relatively recent developments offer new
approaches and insights for enhancing control
measures. Two non-controlled studies, one in
Switzerland, where the prevalence of MRSA is
relatively low, and the other in the UK, where
MRSA is endemic, have shown that rapid molecu-
lar methods using PCR to detect MRSA can have
a beneficial impact on control of MRSA in ICUs
[25,26]. The real challenges were highlighted
when mathematical modelling of MRSA trans-
mission was used to explore the conditions under
which isolation policies can successfully control
MRSA, both in preventing the establishment of an
endemic MRSA situation, and in eradicating
MRSA from settings in which it is already
endemic [27].
A recent stochastic three-hospital model and an
analytical one-hospital model, designed to quan-
tify the effectiveness of different infection control
measures and to predict the effects of rapid
molecular diagnostic testing, have revealed some
interesting findings [28]. The ‘search-and-destroy’
approach to aggressive MRSA control, as prac-
tised in The Netherlands, can be effective in an
environment with high MRSA endemicity, but
may take 6–12 years to have an effect, while the
isolation of patients with MRSA in the absence of
additional control measures is ineffective. Rapid
PCR-based testing to detect nasal carriage of
MRSA is more effective in low-endemicity set-
tings, in which this approach can potentially
reduce isolation requirements by >90%, as
opposed to high-endemicity settings, in which
isolation requirements are reduced by only 20%
[28].
CONCLUSIONS
National MRSA guidelines per se are not a pan-
acea to prevent and control all healthcare infec-
tions or to improve the quality of patient care, as
the necessary resources and the full implementa-
tion of best practice are essential. However,
national guidelines highlight what is required,
set a standard of expectations, and indicate the
priority that national agencies give to this area.
Many published national guidelines review the
literature and use similar, if not identical, criteria
to assess the evidence and determine the strength
of their recommendations. However, all guide-
lines need to be adapted for local use to reflect
practical considerations.
It is ironic that the country with very lowMRSA
prevalence rates, i.e., The Netherlands, has the
simplest set of guidelines (http://www.wip.nl/
UK/free_content/Richtlijnen/ MRSA(1). df), in
which the strength of the evidence is not assessed.
The Dutch success in the control of MRSA could
be related to the clarity of their guidelines, which
may result in better compliance by healthcare
practitioners than would be achieved using guide-
lines that are lengthy and complex. However, it is
more likely that the Dutch success is a result of the
backing and resources allocated to this issue in
The Netherlands by national agencies and the
Dutch government over many years. There has
been greater emphasis on prevention in The
Netherlands, leading to fewer downstream costs
arising from infections caused by MRSA, e.g.,
prolonged hospital stays and the use of more
expensive antimicrobial agents for the treatment
of MRSA infections.
National guidelines usually reflect the needs
and aspirations of a particular country. In coun-
tries in which MRSA is endemic, the main focus
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may realistically be on control or damage limita-
tion, e.g., reducing the numbers of patients with
MRSA BSI. Where MRSA rates are very low and
MRSA is not endemic, the aim is on prevention in
order to maintain hospitals and healthcare insti-
tutions that are relatively free of MRSA. Although
the measures required (i.e., surveillance, isolation,
etc.) are similar in both settings, the capacity to
fully implement them may not be; e.g., where
MRSA is endemic, there may be insufficient
isolation ⁄ cohorting facilities. Mathematical mod-
elling is helpful in predicting the impact of
various measures in settings of low and high
endemicity, and also in confirming what can and
should be done, given the commitment and
available resources.
There may also be a place for international
agreement in the drafting of guidelines, includ-
ing the criteria used to assess the evidence and
the subject areas to be covered. Nonetheless,
consensus and the opinion of a panel of appro-
priate experts are important when the evidence
is either absent or not based on well-conducted
scientific studies. National bodies should not shy
away from these factors when considering some
aspects of control measures. Finally, national
guidelines highlight the need for the allocation
of the resources required to control and prevent
MRSA, and indicate areas in which better-
conducted studies and research should be
undertaken.
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